KFDA approves BMS' Baraclude, a B viral hepatitis therapy.
The mode of Baraclude's action is to reduce the viral infection to the host cells by blocking its proliferation of HBV (hepatitis B virus), which is indicated for the B hepatitis viral infected adults ove...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
